Founder & CEO (PreSeed Health tech) - Cognitive Decline Early Detection Platform at Founders Factory

<p style="min-height:1.5em">Founders Factory builds and funds startups together with exceptional entrepreneurs and the world's leading companies. Created by IPO-exited founders, we offer founders capital, operational support from a team of hands-on experts, and unrivalled access to a coalition of industry-leading corporate partners. Since 2015, Founders Factory’s 450+ portfolio companies have secured 500+ pilots and commercial contracts with our partners.</p><p style="min-height:1.5em">Our Studio partners with entrepreneurs at day one, developing new ideas, technologies and business models into high-growth companies. In partnership with a leading global industrial healthcare partner, we are building a new portfolio of healthcare ventures.</p><p style="min-height:1.5em"></p><h2><strong>About the Venture</strong></h2><p style="min-height:1.5em">Over 55 million people worldwide live with dementia, and the number is projected to triple by 2050. In the US alone, Alzheimer's and related dementias cost $345 billion annually in direct care — and by the time most patients receive a diagnosis, years of irreversible decline have already occurred.</p><p style="min-height:1.5em">The clinical consensus is clear: earlier detection transforms outcomes. Emerging treatments like lecanemab (Leqembi) and donanemab work best — or only — in early-stage disease. But today's diagnostic pathway is reactive: a patient or family member notices something wrong, waits months for a specialist, and undergoes episodic cognitive testing that captures a snapshot, not a trajectory.</p><p style="min-height:1.5em">We are building a continuous, ambient home monitoring platform that detects the earliest behavioural and physiological signals of cognitive and neurological decline — before the patient or family notices. Using our partner’s industrial-grade radar sensors (60GHz, ceiling-mounted, no cameras, no wearables), the system builds a behavioural baseline for each individual: gait patterns, sleep architecture, daily activity rhythms, bathroom frequency. When subtle but clinically meaningful changes emerge — shorter stride, more night-time awakenings, reduced activity range — the platform flags them to the care team and family, enabling intervention months or years earlier than current practice.</p><p style="min-height:1.5em">The initial wedge is the US market, where the convergence of FDA-cleared digital therapeutics, Medicare reimbursement pathways for remote patient monitoring, and the arrival of disease-modifying treatments creates unprecedented commercial pull for early-detection infrastructure. The remote patient monitoring market is $27.7B globally (2024), projected to reach $57–88B by 2030.</p><p style="min-height:1.5em">Beyond detection, the platform becomes the caregiver's operating system: contextualised alerts, care coordination, family reporting, and a longitudinal dataset that compounds with every patient monitored — the evidence base that clinicians, payers, and pharm